Assertio Therapeutics (ASRT) Tops Q2 EPS by 1c

Assertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.19, $0.01 better than the analyst estimate of $0.18. Revenue for the quarter came in at $40.1 million versus the consensus estimate of $39.83 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c
• Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance